Evidence review
How to Microdose GLP-1: The Honest Step-by-Step
How people microdose GLP-1, step by step — and the honest caveats: no clinical protocol exists, it's off-label, and the measuring step is where it goes wrong.
Written Lena Ortiz
On this page
Editorial pick
CoreAge Rx
$79–$129/mo flat
Doctor-reviewed low-dose GLP-1 protocols with flat pricing and built-in human support.
Check availability- Category
- Telehealth · GLP-1 microdose
- Pricing
- Flat monthly price
- Support
- Nurse + dietitian consults
- Labs
- No labs required
Advertising disclosure · an affiliate partner. We may earn a commission at no extra cost to you.
Popular alternative
Found
Established, physician-designed weight-care telehealth with a broad formulary, real coaching, and a new GLP-1 microdosing program.
From $99/mo (compounded, varies)
Check Found availabilityIf you've searched "how to microdose semaglutide" or "how to microdose tirzepatide," you've probably found confident step-by-step walkthroughs that read like a recipe. This page describes the same steps plainly — what the practice actually involves, in order — but it is honest about the thing those walkthroughs skip: there is no clinical protocol for microdosing GLP-1. No trial has tested it, no agency or manufacturer publishes a microdose schedule, and the whole regimen is off-label and almost always built on compounded product. So read this as a description of how the practice is done and where it goes wrong, not as instructions to do it, and not as medical advice. The single most important takeaway up front: the step where people get hurt is the measuring, not the milligram target.
Before any steps: the honesty layer
Everything below is extrapolated from how full-dose GLP-1 drugs are dosed and reconstituted — not from a microdosing study, because none exists. The only clinical literature specifically on microdosing is cautionary: it describes a practice that grew out of GLP-1 compounding restrictions and warns about dosing errors, pen and vial manipulation, medication sharing, and unregulated sourcing1. And microdosing almost always uses compounded GLP-1, because approved pens aren't sold in microdose strengths — a pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting for preparation errors, contamination, and dosing mistakes2. None of the steps that follow are validated. The honest first step is a conversation with a qualified clinician.
How the practice is done (no validated protocol)
Step 1
Prescription + compounded product
Licensed pharmacy under a prescriber — not a grey-market 'research' vial. Sourcing is where it goes right or wrong.
Step 2
Reconstitute and do the math
Rehydrate powder with bacteriostatic water; the milligram-to-units conversion is where a tenfold overdose happens.
Step 3
Start low, hold ≥4 weeks
Borrowed from approved schedules; gives the gut time to accommodate before any change.
Step 4
Inject weekly, track honestly
Subcutaneous once weekly; expect a smaller, slower effect than full doses.
Step 5
Raise, hold, or stop
Escalate no sooner than every 4 weeks and only for a real plateau; stopping tends to bring weight back.
Step 1 — Get a legitimate prescription and product
The defensible path starts with a prescriber, not a marketplace. Because there's no microdose-strength approved pen, a microdose is typically dispensed as a compounded vial of semaglutide or tirzepatide from a licensed pharmacy under a prescription. The grey-market alternative — "research" peptides sold "not for human use" — is exactly the unregulated sourcing the microdosing literature warns about1, with no guarantee of identity, purity, or concentration. Sourcing is the first place the practice goes right or wrong. We cover the legal status in is compounded microdose GLP-1 still legal in 2026? and the safety picture in is compounded / microdosed GLP-1 safe?.
Step 2 — Reconstitute (if it's a powder) and do the math carefully
Compounded GLP-1 often ships as a freeze-dried powder you rehydrate with bacteriostatic water before drawing it up. The arithmetic is grade-school dilution math, but it has one step where a tenfold slip turns a microdose into a large overdose: converting your milligram target into "units" on an insulin syringe. This unit-conversion step — not the milligram goal — is where the real danger lives. Get the concentration and the syringe units straight before anything goes near your skin. We walk through the full math in how to reconstitute and measure a compounded GLP-1 microdose, and our microdose calculator does the concentration arithmetic for you as a planning aid — it sits alongside the rest of the free calculators on this site, including a reconstitution helper and a titration planner.
Step 3 — Start low and hold (the cadence borrowed from approved schedules)
There's no microdose schedule, so the only sane cadence is the one borrowed from how approved GLP-1 drugs are escalated: start at a low weekly dose and hold it for at least four weeks before changing anything. Wegovy's label, for example, starts at 0.25 mg once weekly for four weeks and then titrates no sooner than every four weeks3. That four-week spacing isn't arbitrary — it gives the gut time to accommodate the drug's slowed gastric emptying, which is what lets the dominant dose-related side effect (nausea) settle before any change4. Going low and holding is the entire point of microdosing; rushing the cadence throws away its only real advantage. See the full framework in when and how to increase your GLP-1 microdose.
Step 4 — Inject, track, and judge honestly
GLP-1s are injected subcutaneously once weekly. From there, the practice is mostly observation: track appetite ("food noise"), side effects, and weight, and judge the dose only after holding it long enough to mean something. Be realistic about what a low dose can do. Every proven GLP-1 result came from full doses — semaglutide 2.4 mg produced about 15% mean weight loss in STEP 15 — and the best dose-finding data show effects scaling with dose: roughly −6% at the lowest dose tested up to −13.8% at the highest in a phase 2 trial6. A microdose sits below the bottom of that curve, so the honest expectation is a smaller effect, arriving slowly. See the GLP-1 microdosing results timeline and how much weight can you lose microdosing GLP-1?.
The honest bottom line
If you take nothing else from this page
- There is no clinical microdose protocol — every step is extrapolated from full-dose dosing and reconstitution.
- It's off-label and almost always compounded, with documented preparation-error and contamination signals.
- The danger is the measuring step (mg → insulin-syringe units), not the milligram target — a tenfold slip is an overdose.
- Start low, hold at least 4 weeks, and escalate no sooner than every 4 weeks, only for a real plateau.
- Expect a smaller, slower effect than full doses — a microdose sits below the bottom of the dose-response curve.
- Do it with a clinician who can prescribe, monitor, and catch the math error — not from a marketing page.
Step 5 — Decide when to raise, hold, or stop
The escalation rule borrowed from approved schedules: raise the dose no sooner than every four weeks, and only for a genuine, sustained plateau while you're tolerating the current dose well — not impatience3. Two honest endpoints matter. First, if you find yourself escalating into standard therapeutic doses, you're no longer microdosing — you're on a GLP-1, and the cleaner move is a properly prescribed, approved product. Second, the benefit tracks ongoing exposure: in STEP 4, people who stopped semaglutide regained weight while those who continued held their loss7. This is an indefinite, supervised commitment, not a quick fix. For stopping, see how to taper off GLP-1.
The honest bottom line
How do people microdose GLP-1? Prescription and compounded product, careful reconstitution and unit math, a low starting dose held at least four weeks, weekly subcutaneous injection with honest tracking, and conservative escalation only for a real plateau. But every step is extrapolated, not validated — there is no microdose protocol, it's off-label, it usually relies on compounded product with documented quality signals, and the measuring step is where overdoses happen. If you're considering it, do it with a clinician who can prescribe, monitor, and catch the math error before it matters.
For the wider context, start with the pillar microdosing GLP-1: what the evidence actually shows and the honest verdict is microdosing GLP-1 legit or hype?. To compare providers on price and oversight, see our GLP-1 microdose rankings hub.
Frequently asked
Is there a clinical protocol for how to microdose GLP-1?
No. No trial, agency, or manufacturer publishes a microdose schedule. Everything circulating online is extrapolated from how full-dose GLP-1 drugs are dosed and reconstituted. The only clinical literature specifically on microdosing is cautionary, warning about dosing errors and unregulated sourcing. It is off-label and unvalidated, so it should be done with a clinician, not self-directed.
What is the most dangerous step in microdosing GLP-1?
The measuring step — converting your milligram target into 'units' on an insulin syringe — not the milligram goal itself. A tenfold slip in that conversion turns a microdose into a large overdose. Compounded product adds further risk, with pharmacovigilance data showing elevated reporting for preparation errors and contamination. Getting the concentration and syringe-unit math right is the whole safety game.
How low should you start when microdosing GLP-1, and how often can you increase?
The only sane cadence is the one borrowed from approved schedules: start at a low weekly dose and hold it at least four weeks before changing anything, then raise no sooner than every four weeks and only for a genuine, sustained plateau while tolerating the dose well. The four-week spacing lets the gut accommodate the drug and dose-related nausea settle. None of this is a validated microdose schedule.
Where do you get GLP-1 for microdosing?
The defensible path is a prescription filled as a compounded vial at a licensed pharmacy, because approved pens aren't sold in microdose strengths. The grey-market route — 'research' peptides sold 'not for human use' — is exactly the unregulated sourcing the microdosing literature warns against, with no guarantee of identity, purity, or concentration.
How much weight will microdosing GLP-1 cause?
Likely less than full-dose results, and slowly, and it's unproven. Full-dose semaglutide produced about 15% weight loss in STEP 1, and dose-finding data show effects shrinking as the dose drops. A microdose sits below the bottom of that curve, so expect a smaller, slower effect — and remember the benefit depends on staying on it, since stopping tends to bring weight back.
References
- Trainer N, et al. (2026). The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners. https://pubmed.ncbi.nlm.nih.gov/42201545/
- McCall KL, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. https://pubmed.ncbi.nlm.nih.gov/40285721/
- Novo Nordisk (manufacturer label) (2024). WEGOVY (semaglutide) injection — FDA prescribing information (Dosage and Administration; escalation every 4 weeks from 0.25 mg). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/29617641/
- Wilding JPH, et al. (STEP 1) (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- O'Neil PM, et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/30122305/
- Rubino D, et al. (STEP 4) (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
How to Get Microdosing Tirzepatide: Routes, Costs & Honest Caveats
There is no FDA-approved microdose of tirzepatide. Here are the real routes people use to get it, what they cost, the legal status, and the risks.
Microdosing GLP-1 for Perimenopause & Menopause: Honest Evidence
Women report appetite and energy help from low-dose GLP-1 in menopause. But no microdose trial exists, it's off-label, and the muscle-loss risk is real.
Does Microdosing GLP-1 Help PCOS? An Honest Evidence Check
Full-dose GLP-1 drugs improve weight and metabolism in PCOS trials. But no microdose study exists, it's off-label, and lifestyle plus metformin stay front-line.
Microdosing GLP-1: What the Evidence Actually Shows
An honest, citation-backed look at GLP-1 microdosing — an unstudied, off-label practice. What the trials prove, and why less dose means less effect.
GLP-1 Microdosing for "Metabolic Optimization" & Longevity: Evidence Check
Does a GLP-1 microdose optimize metabolism or extend lifespan? No longevity RCT exists at any dose — and none at microdoses. The honest evidence check.
Who's Microdosing GLP-1, and Why
Who microdoses GLP-1 and the motivations behind it — weight maintenance, side-effect avoidance, cost, longevity. An honest look at an unproven, off-label trend.